Evidence map›Paper›PMID 26682738›Full record

ArticleJapanese journal of radiology2016

Re-irradiation of recurrent anaplastic ependymoma using radiosurgery or fractionated stereotactic radiotherapy.

Taro Murai, Kengo Sato, Michio Iwabuchi, Yoshihiko Manabe, Hiroyuki Ogino, Hiromitsu Iwata, Koshi Tatewaki, Naoki Yokota, Seiji Ohta, Yuta Shibamoto

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group.Clinical and translational radiation oncology · 2027
    Review
  4. Article
  5. Prognostic Factors and Survival Outcomes of Intracranial Ependymoma Treated with Multimodality Approach.Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Taro MuraiDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. taro8864@yahoo.co.jp.
Kengo SatoDepartment of Neurosurgery, Japanese Red Cross Medical Center, Tokyo, Japan.
Michio IwabuchiDepartment of Neurosurgery, Japanese Red Cross Medical Center, Tokyo, Japan.
Yoshihiko ManabeDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Hiroyuki OginoDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.
Hiromitsu IwataDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.
Koshi TatewakiYokohama CyberKnife Center, Yokohama, Japan.
Naoki YokotaRadiation Oncology Center, Suzukake Central Hospital, Hamamatsu, Shizuoka, Japan.
Seiji OhtaDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.
Yuta ShibamotoDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRecurrent ependymomas were retreated with stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT). The efficacy, toxicities, and differences between SRS and FSRT were analyzed.

methodsEight patients with recurrent ependymomas fulfilling the criteria described below were evaluated. Inclusion criteria were: (1) the patient had previously undergone surgery and conventional radiotherapy as first-line treatment; (2) targets were located in or adjacent to the eloquent area or were deep-seated; and (3) the previously irradiated volume overlapped the target lesion.

resultsFSRT was delivered to 18 lesions, SRS to 20 lesions. A median follow-up period was 23 months. The local control rate was 76 % at 3 years. No significant differences in local control were observed due to tumor size or fractionation schedule. Lesions receiving >25 Gy/5 fr or 21 Gy/3 fr did not recur within 1 year, whereas no dose-response relationship was observed in those treated with SRS. No grade ≥2 toxicity was observed.

conclusionOur treatment protocol provided an acceptable LC rate and minimal toxicities. Because local recurrence of tumors may result in patient death, a minimum dose of 21 Gy/3 fr or 25 Gy/5 fr or higher may be most suitable for treatment of these cases.

Indexed as

Dose Fractionation, RadiationRadiosurgeryRe-IrradiationAdolescentAdultBrain NeoplasmsChildEpendymomaFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalTreatment OutcomeYoung AdultCyberKnifeFractionated stereotactic radiotherapyRecurrent ependymomaRe-irradiation

Identifiers

PMID26682738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.